Literature DB >> 21392565

Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration.

Cheng-Feng Luo1, Mu Yuan, Min-Sheng Chen, Shi-Ming Liu, Liu Zhu, Bi-Yun Huang, Xia-Wen Liu, Wen Xiong.   

Abstract

Puerarin has various pharmacological effects; however, poor water-solubility and low oral bioavailability limit its clinical utility. A delivery system of solid lipid nanoparticles could enhance its oral absorption. The objective of this study was to investigate the pharmacokinetics, tissue distribution and relative bioavailability of puerarin in rats after a single dose intragastric administration of puerarin solid lipid nanoparticles (Pue-SLNs). The puerarin concentrations in plasma and tissues were determined by rapid resolution liquid chromatography electrospray ionization-tandem mass spectrometry. The C(max) value of puerarin after the administration of Pue-SLNs was significantly higher than that obtained with puerarin suspension (0.33±0.05 μg/mL vs. 0.16±0.06 μg/mL, P<0.01). The T(max) value after the administration of the Pue-SLNs was significantly shorter than that after puerarin suspension administration (40±0 min vs. 110±15.49 min, P<0.01). The AUC(0→t) values of puerarin were 0.80±0.23 mg h/L, and 2.48±0.30 mg h/L after administration of the puerarin suspension and Pue-SLNs, respectively. Following administration of the Pue-SLNs, tissue concentrations of puerarin also increased, especially in the target organs such as the heart and brain. These data suggest that SLNs are a promising delivery system to enhance the oral bioavailability of puerarin.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21392565     DOI: 10.1016/j.ijpharm.2011.02.064

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  35 in total

Review 1.  Oral bioavailability: issues and solutions via nanoformulations.

Authors:  Kamla Pathak; Smita Raghuvanshi
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

2.  Puerarin-7-O-glucuronide, a water-soluble puerarin metabolite, prevents angiotensin II-induced cardiomyocyte hypertrophy by reducing oxidative stress.

Authors:  Ning Hou; Bin Cai; Cai-Wen Ou; Zhen-Hui Zhang; Xia-Wen Liu; Mu Yuan; Gan-Jian Zhao; Shi-Ming Liu; Long-Gen Xiong; Jian-Dong Luo; Cheng-Feng Luo; Min-Sheng Chen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-16       Impact factor: 3.000

3.  Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model.

Authors:  Deepak Chitkara; Sanjay K Nikalaje; Anupama Mittal; Mahesh Chand; Neeraj Kumar
Journal:  Drug Deliv Transl Res       Date:  2012-04       Impact factor: 4.617

Review 4.  Nanodelivery of phytobioactive compounds for treating aging-associated disorders.

Authors:  Oleh Lushchak; Olha Strilbytska; Alexander Koliada; Alina Zayachkivska; Nadia Burdyliuk; Ihor Yurkevych; Kenneth B Storey; Alexander Vaiserman
Journal:  Geroscience       Date:  2019-11-04       Impact factor: 7.713

5.  Enhancing both oral bioavailability and brain penetration of puerarin using borneol in combination with preparation technologies.

Authors:  Tao Yi; Dandan Tang; Fan Wang; Jiqiong Zhang; Jiao Zhang; Jirui Wang; Xiaoyu Xu; Jifen Zhang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

6.  Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery.

Authors:  Patrícia Severino; Tatiana Andreani; Ana Sofia Macedo; Joana F Fangueiro; Maria Helena A Santana; Amélia M Silva; Eliana B Souto
Journal:  J Drug Deliv       Date:  2011-11-24

7.  Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles.

Authors:  Wenrui Wang; Rongrong Zhu; Qian Xie; Ang Li; Yu Xiao; Kun Li; Hui Liu; Daxiang Cui; Yihan Chen; Shilong Wang
Journal:  Int J Nanomedicine       Date:  2012-07-17

8.  In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration.

Authors:  Min Fang; Yilin Jin; Wei Bao; Hui Gao; Mengjin Xu; Di Wang; Xia Wang; Ping Yao; Liegang Liu
Journal:  Int J Nanomedicine       Date:  2012-10-09

9.  Metabolic profile of puerarin in rats after intragastric administration of puerarin solid lipid nanoparticles.

Authors:  Cheng-Feng Luo; Ning Hou; Juan Tian; Mu Yuan; Shi-Ming Liu; Long-Gen Xiong; Jian-Dong Luo; Min-Sheng Chen
Journal:  Int J Nanomedicine       Date:  2013-03-04

10.  Curcuma longa L. as a therapeutic agent in intestinal motility disorders. 2: Safety profile in mouse.

Authors:  Matteo Micucci; Rita Aldini; Monica Cevenini; Carolina Colliva; Silvia Spinozzi; Giulia Roda; Marco Montagnani; Cecilia Camborata; Luca Camarda; Alberto Chiarini; Giuseppe Mazzella; Roberta Budriesi
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.